
CNTX
Context Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.000
Open
0.970
VWAP
0.89
Vol
387.84K
Mkt Cap
79.84M
Low
0.850
Amount
346.58K
EV/EBITDA(TTM)
--
Total Shares
75.00M
EV
-9.52M
EV/OCF(TTM)
--
P/S(TTM)
--
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company, which is engaged in advancing T cell engaging (TCE) bispecific antibodies (bsAb) for solid tumors. It is building a portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (CLDN6) x CD3 TCE, CT-95, a Mesothelin (MSLN) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (Nectin-4) x CD3 TCE. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. CT-95 is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. Nectin-4 is a target for cancer therapy using a traditional antibody-drug conjugate, but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the acidic tumor microenvironment.
Show More
5 Analyst Rating

405.62% Upside
Wall Street analysts forecast CNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTX is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy

405.62% Upside
Current: 0.890

Low
4.00
Averages
4.50
High
5.00

405.62% Upside
Current: 0.890

Low
4.00
Averages
4.50
High
5.00
Piper Sandler
Overweight
downgrade
$4
2025-06-26
Reason
Piper Sandler
Price Target
$4
2025-06-26
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on Context Therapeutics to $4 from $4.50 and keeps an Overweight rating on the shares after assuming coverage. Context Therapeutics is focused on the emerging T-cell engager modality, which has been validated by several recent clinical milestones and strategic acquisitions, the analyst tells investors in a research note.
William Blair
Matt Phipps
Buy
Initiates
n/a
2025-04-21
Reason
William Blair
Matt Phipps
Price Target
n/a
2025-04-21
Initiates
Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$9
2025-04-09
Reason
D. Boral Capital
Jason Kolbert
Price Target
$9
2025-04-09
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$5
2025-03-21
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$5
2025-03-21
Reiterates
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$9
2025-03-21
Reason
D. Boral Capital
Jason Kolbert
Price Target
$9
2025-03-21
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$9
2025-01-15
Reason
D. Boral Capital
Jason Kolbert
Price Target
$9
2025-01-15
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Context Therapeutics Inc (CNTX.O) is -3.18, compared to its 5-year average forward P/E of -2.80. For a more detailed relative valuation and DCF analysis to assess Context Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-2.80
Current PE
-3.18
Overvalued PE
-0.40
Undervalued PE
-5.20
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-0.19
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.32
Undervalued EV/EBITDA
-1.70
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
+44.61%
-5.53M
Operating Profit
FY2025Q1
YoY :
+24.80%
-4.58M
Net Income after Tax
FY2025Q1
YoY :
-78.26%
-0.05
EPS - Diluted
FY2025Q1
-5.06M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
3
107.1K
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
598.2K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
3
107.1K
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CNTX News & Events
Events Timeline
2025-05-29 (ET)
2025-05-29
07:32:46
Context Therapeutics appoints Chagin as Chief Medical Officer

2025-05-05 (ET)
2025-05-05
17:22:15
Context Therapeutics CMO Claudio Dansky Ullmann to depart

2025-04-30 (ET)
2025-04-30
07:34:56
Context Therapeutics presents preclinical data on CT-95

Sign Up For More Events
Sign Up For More Events
News
4.0
06-26BenzingaPiper Sandler Reiterates Overweight on Context Therapeutics, Lowers Price Target to $4
1.0
06-02NewsfilterContext Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
5.0
05-29NewsfilterContext Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
Sign Up For More News
People Also Watch

ANL
Adlai Nortye Ltd
1.500
USD
0.00%

LEE
Lee Enterprises Inc
6.960
USD
+4.50%

RANI
Rani Therapeutics Holdings Inc
0.416
USD
-0.24%

OPAD
Offerpad Solutions Inc
2.140
USD
-4.04%

MSSA
Metal Sky Star Acquisition Corp
0
USD
-6.52%

ISPO
Inspirato Inc
3.080
USD
-4.05%

PEPG
PepGen Inc
1.350
USD
0.00%

SQNS
Sequans Communications SA
2.700
USD
-9.09%

INO
Inovio Pharmaceuticals Inc
1.390
USD
+1.46%

YTRA
Yatra Online Inc
0.950
USD
0.00%
FAQ

What is Context Therapeutics Inc (CNTX) stock price today?
The current price of CNTX is 0.89 USD — it has decreased -2.41 % in the last trading day.

What is Context Therapeutics Inc (CNTX)'s business?

What is the price predicton of CNTX Stock?

What is Context Therapeutics Inc (CNTX)'s revenue for the last quarter?

What is Context Therapeutics Inc (CNTX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Context Therapeutics Inc (CNTX)'s fundamentals?

How many employees does Context Therapeutics Inc (CNTX). have?
